Regeneron antibody secures FDA win; Yancopoulos in expansive Q&A; Biogen’s Reata bidding war details revealed; Peter Marks on accelerated approvals; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With most second quarter earnings in the rearview mirror,…
Click here to view original post